CAPLYTA SAVINGS PROGRAM
With the CAPLYTA Copay Savings Card, eligible* patients may pay as little as $0 for their first fill and $15 for refills of CAPLYTA.
Two Ways to Claim Your Copay Savings Card
Download and print your Savings Card
Download and print your savings card. Then, simply bring it to your pharmacy, show it to the pharmacist—and start saving on your CAPLYTA prescriptions.
Download my Savings Card
Download and print your Savings Card
Download and print your savings card. Then, simply bring it to your pharmacy, show it to the pharmacist—and start saving on your CAPLYTA prescriptions.
Download my Savings Card
Download an electronic card to your phone
Text “CAPLYTA” to 26789

Show it to your pharmacist and receive your savings, plus refill reminders.

Message & Data Rates may apply. Message frequency varies. Terms & Conditions apply: www.engagedrx.com/CAP. Once enrolled, text HELP for help. Text STOP to end.

Text “CAPLYTA” to 26789

Show it to your pharmacist and receive your savings, plus refill reminders.

Message & Data Rates may apply. Message frequency varies. Terms & Conditions apply: www.engagedrx.com/CAP. Once enrolled, text HELP for help. Text STOP to end.

* Program Terms, Conditions and Eligibility Criteria: This offer is valid for eligible new or existing patients who are filling a prescription for CAPLYTA™.

To be eligible for this offer patients must be 18 years of age or older and less than 65 years old, residents of the United States, excluding Puerto Rico, and have a valid prescription for CAPLYTA. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). This offer is not valid for cash paying patients. This offer is not insurance, has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer. This offer is good only at participating retail pharmacies. This card may not be redeemed for cash. Void if prohibited by law, taxed, or restricted. Eligible patients may pay as little as $0 per 30-day supply on the first fill, up to the maximum lifetime benefit based on current list price. On subsequent uses, patients may pay as little as $15, up to the maximum benefit of $600. Program benefit calculated on FDA-approved dosing. A valid Prescriber ID# is required on the prescription. By consenting to participate in this offer, you acknowledge and agree to data related to the redemption of this copay card being collected, analyzed, and shared with Intra-Cellular Therapies for market research and/or other purposes related to assessing the CAPLYTA Copay program.

This program is valid through 04/30/2021.

Patients with questions about the CAPLYTA™ Savings Card should call 1-800-639-4047.

Pharmacist: When you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs for this prescription. This offer is not valid for cash paying patients. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the Terms and Conditions and the Restrictions section below.

Pharmacist instructions for a patient with an Eligible Third Party: Submit the claim to the primary Third Party Payer first, then submit the balance due to Change Healthcare as a Secondary Payer as a copay-only billing using a valid Other Coverage Code, (e.g. 03 or 08). Eligible patients may pay as little as $0 per 30-day supply on the first use, up to the maximum lifetime benefit based on current list price. On subsequent uses, patients may pay as little as $15, up to the maximum benefit of $600. Reimbursement will be received from Change Healthcare.

For any questions regarding Change Healthcare online processing, please call the Help Desk at 1-800-422-5604.

Restrictions: This offer is valid in the United States, excluding Puerto Rico. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). This offer is not valid for cash paying patients. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. It is illegal to (or offer to) sell, purchase, or trade this offer. Program expires 04/30/2021. This offer is not transferable and is limited to one offer per person. Not valid if reproduced.

Void where prohibited by law. Program managed by ConnectiveRx on behalf of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc. reserves the right to rescind, revoke, or amend this offer without notice at any time.

 
 

Important Safety Information

Boxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g. allergic dermatitis, papular rash, and generalized rash), and urticaria.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

Drug Interactions: Avoid concomitant use with CYP3A4 inducers, moderate or strong CYP3A4 inhibitors and UGT inhibitors.

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Breastfeeding is not recommended. Avoid use in patients with moderate or severe hepatic impairment.

Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs. placebo were somnolence/sedation (24% vs. 10%) and dry mouth (6% vs. 2%).

Indication
CAPLYTA (lumateperone) is indicated for the treatment of schizophrenia in adults.

Please see full Prescribing Information, including Boxed Warning.

 

CAPLYTA and LYTAlink are trademarks of Intra-Cellular Therapies, Inc.
© Intra-Cellular Therapies, Inc. All rights reserved.
US-CAP-2000084 03/20